Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Investigational Agents With or Without Chemotherapy in Untreated Advanced NSCLC
NCT05635708Phase 2Completed
- Sponsor
- BeiGene
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of gimistotug, alcestobart and BGB-15025 in non-small cell lung cancer (NSCLC) (8 arms), sponsored by BeiGene. Primary endpoint: Confirmed Overall Response Rate at 6 months. Started Feb 2023; status: completed.
02
Drugs
gimistotugalcestobartBGB-15025
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05635708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635708.